Price T Rowe Associates Inc Pliant Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Pliant Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,834,813 shares of PLRX stock, worth $37.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
4,834,813
Previous 4,602,323
5.05%
Holding current value
$37.7 Million
Previous $49.5 Million
9.55%
% of portfolio
0.01%
Previous 0.01%
Shares
12 transactions
Others Institutions Holding PLRX
# of Institutions
175Shares Held
63.3MCall Options Held
245KPut Options Held
373K-
Deep Track Capital, LP Greenwich, CT5.97MShares$46.5 Million2.47% of portfolio
-
Black Rock Inc. New York, NY4.97MShares$38.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.53MShares$27.5 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA3.2MShares$24.9 Million2.34% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.1MShares$24.2 Million1.25% of portfolio
About PLIANT THERAPEUTICS, INC.
- Ticker PLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,682,000
- Market Cap $379M
- Description
- Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a tri...